Certolizumab in Recurrent Implantation Failure (RIF) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Certolizumab in Recurrent Implantation Failure (RIF) — Stella

Home/Recurrent Unexplained Implantation Failure/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Unexplained Implantation Failure trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

France

Saint-Antoine Hospital - APHP, Paris

Key details

Phase

Large-scale testing

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment target

~161 participants

Started

November 2023

Primary completion

April 2029

Age range

18 Years – 40 Years

Sex

Female only

Last updated December 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.